Salud financiera de hoja de balance de AlloVir
Salud financiera controles de criterios 6/6
AlloVir tiene un patrimonio de los accionistas total de $145.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $190.8M y $45.0M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
Ratio de cobertura de intereses | n/a |
Efectivo | US$140.53m |
Patrimonio | US$120.44m |
Total pasivo | US$23.70m |
Activos totales | US$144.14m |
Actualizaciones recientes sobre salud financiera
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Recent updates
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully
Feb 09Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Oct 03Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Jun 23Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Mar 02Is AlloVir (NASDAQ:ALVR) In A Good Position To Deliver On Growth Plans?
Nov 11AlloVir GAAP EPS of $0.69 beats by $1.42
Aug 04AlloVir stock surges on $126.6M securities offering
Jul 27Is AlloVir (NASDAQ:ALVR) In A Good Position To Invest In Growth?
Jul 27Here's Why We're Not Too Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Situation
Mar 21AlloVir: A Comparative Study Of Its Manufacturing Process
Feb 07We're Not Very Worried About AlloVir's (NASDAQ:ALVR) Cash Burn Rate
Nov 02AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
Oct 02AlloVir, Inc.'s (NASDAQ:ALVR) Intrinsic Value Is Potentially 24% Below Its Share Price
Aug 06We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Jul 01AlloVir EPS misses by $0.08
May 06AlloVir (NASDAQ:ALVR) Is In A Good Position To Deliver On Growth Plans
Apr 01This Insider Has Just Sold Shares In AlloVir, Inc. (NASDAQ:ALVR)
Feb 07Is AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
Jan 08FDA clears AlloVir's ALVR106 application in respiratory viruses
Dec 17Allovir's COVID-19 therapy saw anti-viral activity in pre-clinical data
Dec 07We Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
Dec 04AlloVir EPS misses by $0.28
Nov 10Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($187.6M) de ALVR superan a sus pasivos a corto plazo ($28.4M).
Pasivo a largo plazo: Los activos a corto plazo de ALVR ($187.6M) superan a sus pasivos a largo plazo ($16.6M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ALVR está libre de deudas.
Reducción de la deuda: ALVR no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 6.3%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ALVR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ALVR dispone de suficiente cash runway para 2.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 31.9% cada año.